Perception Neuroscience & Otsuka Pharmaceutical To Collaborate In Japan On Development Of Ketamine Compound For Depression Treatment

Perception Neuroscience, Inc. (Perception), an atai Life Sciences (atai) company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd. (Otsuka), announced a collaboration and licensing agreement for the development and commercialization of Perception's lead molecule, PCN-101 (R-ketamine) in Japan as a potential treatment for mood disorders such as major depressive disorder (MDD) and treatment-resistant depression (TRD). Outside of Japan, Perception is developing PCN-101 to treat TRD.

PCN-101 is a formulation of R-ketamine, a single isomer of ketamine that belongs to a new generation of glutamate receptor modulators, being developed . . .